Cell biology of killer CAR-T cells: improving immunotherapy

Cell biology of killer CAR-T cells: improving immunotherapy

Project details

Immunotherapy recruits the immune system to fight cancer and is being hailed as the largest advancement for cancer treatment since chemotherapy. 

Chimeric antigen receptor T cells (CAR-T) are a form of immunotherapy that have successfully produced long-term remissions for blood cancers, but with limited success for solid cancer. This has raised the question of how to extend these therapies to cover a broader range of malignancies and allow for sustained immune responses. 

This project will investigate features of CAR-T cell biology that are currently blocking successful translation to solid malignancies. We will use a combination of techniques including cell biology, molecular biology, in vivo tumour models and live cell imaging to examine the differences between various structures of CAR-T versus TCR signalling and the formation of long-lived memory cells. 

 

About our research group

Our lab is focussed on understanding the basic cell biology of killer lymphocytes. We use a broad range of techniques to understand signalling, killing, cytokine/chemokine production and the cross-talk between different cells in the immune system. Therefore, our interests combine basic immunological approaches to clinical settings of cancer biology.

Researchers:

Dr Misty Jenkins

Dr Misty Jenkins at a microscope
Dr
Misty
Jenkins
Laboratory Head

Project Type: